Location History:
- Freiburg, DE (2020 - 2021)
- Strasbourg, FR (2013 - 2022)
Company Filing History:
7 out of 1,743 
6 out of 170 
2 out of 2 
Years Active: 2013-2022
Title: Thomas Baumert: Innovator in Hepatitis C Research
Introduction
Thomas Baumert is a prominent inventor based in Strasbourg, France. He has made significant contributions to the field of medical research, particularly in the area of hepatitis C virus (HCV) infection. With a total of 7 patents to his name, Baumert's work focuses on innovative solutions for preventing and treating liver diseases.
Latest Patents
Among his latest patents is the invention of humanized anti-claudin-1 antibodies and their uses. This invention addresses the critical need for effective treatments against hepatitis C virus infection, which is a leading cause of chronic liver disease. The humanized anti-claudin-1 antibody, known as H3L3, has shown promise in preventing HCV infection and curing chronically infected human liver chimeric mice. H3L3 has demonstrated the ability to inhibit HCV pseudoparticle infection of primary human hepatocytes without detectable escape, making it a significant advancement in the field. Additionally, Baumert's work includes a clinical gene signature-based human cell culture model that aids in the screening of compounds for the treatment and prevention of hepatocellular carcinoma (HCC) and cirrhosis.
Career Highlights
Baumert has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Strasbourg. His research has not only contributed to scientific knowledge but has also paved the way for potential therapeutic applications in liver disease management.
Collaborations
Throughout his career, Baumert has collaborated with notable colleagues, including Rajeevkumar Tawar and Eric Robinet. These partnerships have enhanced the scope and impact of his research endeavors.
Conclusion
Thomas Baumert's innovative work in hepatitis C research exemplifies the vital role of inventors in advancing medical science. His contributions continue to inspire future developments in the treatment of liver diseases.